1. Highlights From the 2015 European Multiple Sclerosis Meeting

2. ORATORIO Study

3. ORATORIO Study Methodological Caveats

4. PROMiSe Trial

5. Anti-LINGO-1

6. Challenges in Progressive MS Research

7. Highlights From the 2015 European Multiple Sclerosis Meeting

8. Daclizumab HYP Phase 3 Subanalyses

9. DECIDE Study Subanalyses

10. Sodium Channel Blockade

11. LINGO-1 Pathway Knockout

12. Autologous Stem Cell Transplantation

13. OPERA I and OPERA II: Primary End Points

14. OPERA I and OPERA II: MRI Results

15. Highlights From the 2015 European Multiple Sclerosis Meeting

16. Anti-LINGO-1

17. RENEW Study Methods

18. RENEW Results

19. Interpretations of RENEW

20. Future Remyelination Strategies

21. Highlights From the 2015 European Multiple Sclerosis Meeting

22. Brain Atrophy

23. Previous Analysis: Teriflunomide and MRI Measures

24. The Effect of Teriflunomide on Brain Volume Loss: SIENA

25. Dimethyl Fumarate and Pregnancy: Animal Models

26. Dimethyl Fumarate and Pregnancy Registries

27. Alemtuzumab in Highly Active MS

28. Natalizumab: Standard vs Extended Dosing

29. Extended Natalizumab Dosing Results

30. Abbreviations

31. Abbreviations (cont)

32. References

33. References (cont)

34. References (cont)

35. References (cont)